What is the address of CONNECTING PHARMA?

The registered office of CONNECTING PHARMA is located at Edmond Boonenstraat 4, 9000 Gent.

Is CONNECTING PHARMA still active?

Yes. According to the CBE (2 November 2026) CONNECTING PHARMA is active, legal situation “Normale toestand”, started on 20 June 2012.

Is CONNECTING PHARMA registered on Peppol?

Yes, CONNECTING PHARMA is registered on the Peppol network with ID 0208:0846826628.

What is the enterprise number of CONNECTING PHARMA?

The enterprise number of CONNECTING PHARMA is BE0846826628.

When was CONNECTING PHARMA founded?

CONNECTING PHARMA was founded on 20 June 2012.

Who are the directors of CONNECTING PHARMA?

According to the 2025 annual accounts, the directors of CONNECTING PHARMA are: Frederik Deroose.

Is CONNECTING PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 June 2012; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 1 events from the Belgian Official Gazette processed.

How much profit did CONNECTING PHARMA make in 2025?

CONNECTING PHARMA posted a profit after taxes of € 44,241 in financial year 2025.

What is the revenue of CONNECTING PHARMA?

As a small company, CONNECTING PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 68,483.

CONNECTING PHARMA (Private Limited) - Gent - BE0846826628

Q: What does CONNECTING PHARMA do?

CONNECTING PHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 20 June 2012, 1 establishment.

Dossier CONNECTING PHARMA, printed on 3 November 2026 from databakkes.be/en/0846826628/connecting-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CONNECTING PHARMA from Gent, company number BE0846826628, closed financial year 2025 with a result of € 44,241 after tax. For that financial year CONNECTING PHARMA recorded a gross margin of € 68,483 and equity of € 137,271. Compared with financial year 2024, the result moved from € 29,717 to € 44,241. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 25, 2026.

What it is worth Healthy

€ 137,271

▼ 27% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 44,241

▲ 49% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 231,970

▼ 12% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 93,782 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

€ 4,746

▲ € 4,541 vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 4,475

▲ 34% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,320

▲ 59% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 55,707 Gross margin 2022: € 55,707 First fiscal year in the series	€ 78,511 Gross margin 2023: € 78,511 ▲ 41% vs 2022 (€ 55,707) Favourable step	€ 53,879 Gross margin 2024: € 53,879 ▼ 31% vs 2023 (€ 78,511) Unfavourable step	€ 68,483 Gross margin 2025: € 68,483 ▲ 27% vs 2024 (€ 53,879) Favourable step	▲ 27%
Profit after taxes	€ 28,168 Profit after taxes 2022: € 28,168 First fiscal year in the series	€ 35,145 Profit after taxes 2023: € 35,145 ▲ 25% vs 2022 (€ 28,168) Favourable step	€ 29,717 Profit after taxes 2024: € 29,717 ▼ 15% vs 2023 (€ 35,145) Unfavourable step	€ 44,241 Profit after taxes 2025: € 44,241 ▲ 49% vs 2024 (€ 29,717) Favourable step	▲ 49%
Equity	€ 270,242 Equity 2022: € 270,242 First fiscal year in the series	€ 305,388 Equity 2023: € 305,388 ▲ 13% vs 2022 (€ 270,242) Favourable step	€ 186,811 Equity 2024: € 186,811 ▼ 39% vs 2023 (€ 305,388) Unfavourable step	€ 137,271 Equity 2025: € 137,271 ▼ 27% vs 2024 (€ 186,811) Unfavourable step	▼ 27%
Total debts	€ 156,112 Total debts 2022: € 156,112 First fiscal year in the series	€ 207,731 Total debts 2023: € 207,731 ▲ 33% vs 2022 (€ 156,112) Unfavourable step	€ 167,188 Total debts 2024: € 167,188 ▼ 20% vs 2023 (€ 207,731) Favourable step	€ 175,072 Total debts 2025: € 175,072 ▲ 5% vs 2024 (€ 167,188) Unfavourable step	▲ 5%
Cash	€ 113,047 Cash 2022: € 113,047 First fiscal year in the series	€ 409,601 Cash 2023: € 409,601 ▲ 262% vs 2022 (€ 113,047) Favourable step	€ 264,977 Cash 2024: € 264,977 ▼ 35% vs 2023 (€ 409,601) Unfavourable step	€ 231,970 Cash 2025: € 231,970 ▼ 12% vs 2024 (€ 264,977) Unfavourable step	▼ 12%
Land & buildings	€ 5,670 Land & buildings 2022: € 5,670 First fiscal year in the series	€ 1,250 Land & buildings 2023: € 1,250 ▼ 78% vs 2022 (€ 5,670) Unchanged	€ 262 Land & buildings 2024: € 262 ▼ 79% vs 2023 (€ 1,250) Unchanged	€ 0 Land & buildings 2025: € 0 ▼ 100% vs 2024 (€ 262) Unchanged	▼ 100%
Retained profit	€ 251,642 Retained profit 2022: € 251,642 First fiscal year in the series	€ 286,788 Retained profit 2023: € 286,788 ▲ 14% vs 2022 (€ 251,642) Favourable step	€ 186,811 Retained profit 2024: € 186,811 ▼ 35% vs 2023 (€ 286,788) Unfavourable step	€ 137,271 Retained profit 2025: € 137,271 ▼ 27% vs 2024 (€ 186,811) Unfavourable step	▼ 27%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 129,693 Dividend 2024: € 129,693 Unchanged (€ 0) Unchanged	€ 93,782 Dividend 2025: € 93,782 ▼ 28% vs 2024 (€ 129,693) Unchanged	▼ 28%
Bank debt	€ 175 Bank debt 2022: € 175 First fiscal year in the series	€ 244 Bank debt 2023: € 244 ▲ 39% vs 2022 (€ 175) Unfavourable step	€ 205 Bank debt 2024: € 205 ▼ 16% vs 2023 (€ 244) Favourable step	€ 4,746 Bank debt 2025: € 4,746 ▲ € 4,541 vs 2024 (€ 205) Unfavourable step	▲ € 4,541
Balance sheet total	€ 426,355 Balance sheet total 2022: € 426,355 First fiscal year in the series	€ 513,119 Balance sheet total 2023: € 513,119 ▲ 20% vs 2022 (€ 426,355) Unchanged	€ 353,999 Balance sheet total 2024: € 353,999 ▼ 31% vs 2023 (€ 513,119) Unchanged	€ 312,342 Balance sheet total 2025: € 312,342 ▼ 12% vs 2024 (€ 353,999) Unchanged	▼ 12%

Key figures of CONNECTING PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CONNECTING PHARMA?

What happened at CONNECTING PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 25, 2026 New annual accounts for financial year 2025: profit of € 44,241 (▲ 49% vs 2024). Source: NBB ↗
Jul 4, 2012 Incorporation, published in the Gazette. Source: Staatsblad ↗
Jun 20, 2012 New establishment in Gent. KBO

In short

From € 28,168 profit in 2022 to € 44,241 profit in 2025.

Paid € 64,078 in corporate taxes since 2022.

Best year ever: 2025, with € 44,241 profit.

Paid out € 223,475 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Frederik Deroose

CONNECTING PHARMA

Koninklijke Sportduikclub Gentse Dolfijnen

Behind CONNECTING PHARMA is Frederik Deroose. Frederik Deroose is also behind Koninklijke Sportduikclub Gentse Dolfijnen.

Directors

According to the 2025 annual accounts

Frederik Deroose

Director

Also active at: Koninklijke Sportduikclub Gentse Dolfijnen

Establishments

Establishment units

Physical locations of this company

Registered office

Edmond Boonenstraat 4

9000 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Incorporation

4 July 2012 Source: Deed ↗

Deroose, Frederik Dirk(oprichter) 100%

Details

Company number

0846.826.628

VAT number

BE 0846.826.628

Registered office

Edmond Boonenstraat 4, 9000 Gent

Names & denominations

CONNECTING PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

20 June 2012

Peppol

Active · Active since 3 Mar 2023

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Speur- en ontwikkelingswerk op biotechnologisch gebied

Markt- en opinieonderzoek

Activiteiten op het gebied van voeding

Vervaardiging van farmaceutische grondstoffen

Overige menselijke gezondheidszorg, n.e.g.

Vervaardiging van andere organische chemische basisproducten

View on CBE Public ↗ Annual accounts (NBB) ↗

CONNECTING PHARMA

Financials

What happened to CONNECTING PHARMA?

Management

Directors

Establishments

Establishment units

Shareholders according to the Official Gazette deeds

Details

Frequently asked questions